MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from redemption
of short-term...
$54,450K
Proceeds from long-term
investments and marketable...
$39,566K
Proceeds from loan to an
equity method investee
$6,251K
Proceeds from marketable
securities
$2,865K
Total net cash
provided by investing...
$5,443K
Canceled cashflow
$97,689K
Increase (decrease) in
cash and cash...
-$8,473K
Canceled cashflow
$5,443K
Net income (loss)
$64,016K
Deferred tax liabilities
-$7,911K
Stock-based compensation
$5,992K
Accounts payable,
accrued expenses and...
$1,130K
Exchange differences and
interest on deposits
-$830K
Depreciation
$121K
Net changes in
operating lease
$117K
Liability for employee
rights upon retirement
$9K
Investments at fair value
-$64,712K
Purchase of short-term
deposits
$10,948K
Purchase of marketable
securities
$9,846K
Loan to investment in
equity method
$7,000K
Purchase of convertible
note
$3,000K
Real estate
investment
$1,924K
Equity method investee
$250K
Purchase of property and
equipment
$9K
Total net cash used in
operating activities
-$9,145K
Canceled cashflow
$80,126K
Total net cash used in
financing activities
-$4,741K
Effect of exchange rate
changes on cash and cash...
-$30K
Changes in fair value of
investments
-$86,096K
Deferred revenues
-$2,000K
Prepaid expenses and
other current assets
$998K
Deferred income
$105K
Other liabilities
-$60K
Gain on amounts
funded in respect of...
$12K
Repurchase and retirement
of common stock
$4,741K
Back
Back
Cash Flow
source: myfinsight.com
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)